Sign In
Buy CLDX
$38.06
-0.425 (-1.10%)
At Close: Jul 31, 2026
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?
10:41am, Friday, 24'th Jul 2026
Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.
Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss
01:02am, Friday, 24'th Jul 2026
Celldex Therapeutics (NASDAQ: CLDX) said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or secondary endpoints, prompting the company to discontinue development of the
Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript
01:10pm, Wednesday, 22'nd Jul 2026
Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript
Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study
07:29am, Wednesday, 22'nd Jul 2026
Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday said it is ending its Phase 2 clinical trial evaluating barzolvolimab for prurigo nodularis, a chronic condition characterized by intensely itchy ski
Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss
06:03am, Wednesday, 22'nd Jul 2026
Celldex Therapeutics NASDAQ: CLDX said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or secondary endpoints, prompting the company to discontinue development of the dr
Celldex to stop skin disease study after trial setback
04:44pm, Tuesday, 21'st Jul 2026
Celldex Therapeutics said on Tuesday it would discontinue the development of its experimental drug for a skin disease after it failed to meet the main goal and key secondary goals in a mid-stage
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
04:01pm, Tuesday, 21'st Jul 2026
HAMPTON, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline results from the Company's Phase 2 study of barzolvolimab delivered subcutaneously in prurigo nodularis (P
Celldex Announces Planned Transition of Chief Financial Officer
04:01pm, Wednesday, 15'th Jul 2026
HAMPTON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that Sam Martin, Senior Vice President and Chief Financial Officer, has informed the Company of his plans to reti
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the Euro
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that target
-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria ---- Late-breaking poster presentation on CDX-622 -- HAMPTON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) a
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
06:55pm, Thursday, 07'th May 2026
Celldex Therapeutics (CLDX) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $0.81 per share a year ago.
Celldex Reports First Quarter Financial Results and Provides Corporate Update
04:01pm, Thursday, 07'th May 2026
HAMPTON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update.
Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial
08:55am, Thursday, 07'th May 2026
Celldex is positioned as a platform immunology company, leveraging barzolvolimab's mast-cell depletion mechanism beyond chronic urticaria. CLDX's robust cash position ($518.6M at 2025 year-end, $345M
Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?
10:56am, Monday, 04'th May 2026
The mean of analysts' price targets for Celldex (CLDX) points to a 76.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
